EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

From Cold to Constrained: Why MSS Colorectal Cancer Resists Immunotherapy

Christophe Nicot iD

Cancer Biome and Targeted Therapy · 12.05.2026 · 320-327

DOI: 10.66505/cbtt.v1i2.51 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Biome and Targeted Therapy, online erschienen am 12.05.2026. Verfasst von Christophe Nicot. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, USA. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Center for Cancer Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint blockade (ICB) has reshaped the treatment of multiple malignancies. However, its success in colorectal cancer (CRC) has been largely restricted to the minority of tumors exhibiting microsatellite instability-high (MSI-H) status. In contrast, microsatellite-stable (MSS) colorectal cancer remains largely refractory (1, 2). For nearly a decade, this resistance has been framed in deceptively simple terms: MSS tumors are “immune cold,” lack sufficient neoantigens, and therefore fail to respond to checkpoint inhibition. While conceptually convenient, this explanation has proven clinically insufficient. MSS CRC is not immunologically barren; rather, it is immunologically constrained. This commentary examines and contextualizes the accompanying review by Mi et al. on immune resistance in MSS colorectal cancer (3). Mi and colleagues present a timely and integrative reframing of MSS CRC immune failure, arguing that resistance to ICB is driven not by immune absence per se, but by a coordinated network of metabolic, microbial, and microenvironmental constraints that actively suppress immune competence. By integrating insights from tumor immunology, immunometabolism, and microbiome research, the authors propose a tripartite model in which host metabolism, gut dysbiosis, and immune suppression form a self-reinforcing ecosystem that limits the efficacy of checkpoint blockade alone. This reframing clarifies a long-standing misconception and directly informs therapeutic strategy. The persistence of the “cold tumor” paradigm may itself have delayed progress. By attributing failure primarily to the absence of immunogenicity, the field has often underprioritized reversible ecosystem-level barriers such as nutrient deprivation, stromal exclusion, and microbial conditioning. Reframing MSS CRC as constrained rather than inert, therefore, carries not only biological significance but therapeutic urgency.

Schlagwörter

Stichwörter der Autor:innen

MSS colorectal cancerimmune checkpoint blockadeimmune resistanceimmunometabolismmicrobiomemicrosatellite-stable colorectal cancertumor microenvironment

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, USA.

ORCID-Profile: Christophe Nicot

Förderung

  • NCI NIH HHS
  • Center for Cancer Research

Zitieren

APA

Nicot, C. (2026). From Cold to Constrained: Why MSS Colorectal Cancer Resists Immunotherapy. Cancer Biome and Targeted Therapy, 320-327. https://doi.org/10.66505/cbtt.v1i2.51

Vancouver

Nicot C. From Cold to Constrained: Why MSS Colorectal Cancer Resists Immunotherapy. Cancer Biome and Targeted Therapy. 2026:320-327. doi:10.66505/cbtt.v1i2.51

BibTeX
@article{Nicot2026,
  author = {Nicot, Christophe},
  title = {From Cold to Constrained: Why MSS Colorectal Cancer Resists Immunotherapy},
  journal = {Cancer Biome and Targeted Therapy},
  year = {2026},
  pages = {320--327},
  doi = {10.66505/cbtt.v1i2.51}
}
Kostenlos starten →